YAP1 and melanoma: In addition, the correlation of YAP1/TAZ with the MITFlow/AXLhigh phenotype was significant across the TCGA melanoma tumors and clinically resistant melanoma samples amongst which a subset of resistant tumors acquired YAP1 activity along with clinical resistance toward MAPK inhibitors (Fig. 2c–e) [30].